Drug intelligence / Profile preview

N-3C01

Development stage: Phase 2
Lead developer: Yifan Pharmaceutical

Overview

N-3C01 is an investigational biologic therapeutic being developed by Yifan Pharmaceutical for the treatment of tumors. As of early 2024, the drug candidate is in the IND (Investigational New Drug) submission phase, representing the transition from preclinical studies to clinical evaluation. While categorized as a biologic for oncology, specific details regarding its molecular structure—such as whether it is a monoclonal antibody, recombinant protein, or fusion protein—and its exact biological target have not yet been publicly disclosed by the developer.

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on N-3C01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-3C01.

Explore the full profile